Connect Biopharma Holdings Ltd ADR (CNTB) Stock Price, Quote & News

Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquarte...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1040

Website: www.connectbiopharm.com

Address:

3580 CARMEL MOUNTAIN ROAD, SUITE 200, San Diego, United States

YasirTrades Jul. 5 at 3:26 AM

GLMD is running out of time in a good way. The 90-day definitive agreement window from April 28th ends this month. You don’t get many biotech plays under $1 with a $12+ book value and real M&A potential. Low float, strong cash, and a clear catalyst. It’s a ticking time bomb in a setup kind of way. $CABA $ALLR $CNTB $CLRB

0 · Reply

Doozio Jul. 4 at 4:22 PM

$CNTB if Ksha is here da 🧠 must be near. 🐒🍌🧠⏰♾️

0 · Reply

RollingDollars Jul. 3 at 2:42 PM

$CNTB

0 · Reply

kshonstocks Jul. 3 at 2:32 PM

$CNTB on scans, has the higher highs

0 · Reply

mikeywo Jul. 3 at 2:28 PM

$CNTB is this being discovered ? Glad I got in at .61c

0 · Reply

Bcscoatings Jun. 24 at 3:44 PM

$PSTV shorts got what they wanted now time for us to get what we want!! Time to go!! About to break that 100 million in volume !!! $CNTB $IGC

0 · Reply

mikeywo Jun. 24 at 3:33 PM

$CNTB what happened Barry ? You let the momentum up to 1.12$ go to waste.

0 · Reply

Bcscoatings Jun. 20 at 3:56 PM

$PCSA volume insane and still picking up. Reminds me $HCTI it went from .007-.04 huge volume 2 days in a row!!!! Bout to hit big here gain too!! $CNTB $CHSN $ELTP

0 · Reply

TheWings977 Jun. 17 at 9:58 PM

$CNTB back to $1. What’s the minimum to stay listed?

0 · Reply

RollingDollars Jun. 17 at 1:59 PM

$CNTB

0 · Reply

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 3, 2025, 9:00 AM EDT - 4 weeks ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

May 28, 2025, 9:00 AM EDT - 5 weeks ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 20, 2025, 9:00 AM EDT - 6 weeks ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 15, 2025, 9:00 AM EDT - 7 weeks ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 9:00 AM EDT - 7 weeks ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 13, 2025, 9:00 AM EDT - 7 weeks ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Apr 24, 2025, 9:00 AM EDT - 2 months ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Apr 1, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Mar 31, 2025, 4:05 PM EDT - 3 months ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 28, 2025, 4:05 PM EDT - 3 months ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 3, 2025, 8:00 AM EST - 4 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 9 months ago

Attovia Therapeutics Appoints Chief Financial Officer

Oct 9, 2024, 3:55 PM EDT - 9 months ago

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 2, 2024, 4:14 PM EDT - 9 months ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Sep 5, 2024, 4:05 PM EDT - 10 months ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jun 12, 2024, 6:03 PM EDT - 1 year ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 4:15 PM EDT - 1 year ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

May 22, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 1 year ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 12, 2024, 4:30 PM EST - 1 year ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Dec 12, 2023, 6:00 AM EST - 1 year ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Dec 11, 2023, 4:05 PM EST - 1 year ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Nov 21, 2023, 6:03 AM EST - 1 year ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Nov 21, 2023, 6:00 AM EST - 1 year ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 20, 2023, 4:41 PM EST - 1 year ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Sep 12, 2023, 4:15 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Sep 12, 2023, 6:00 AM EDT - 1 year ago

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Aug 24, 2023, 6:21 PM EDT - 2 years ago

Connect Biopharma to Participate in Upcoming September Investor Conferences

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Jun 1, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

Mar 18, 2023, 2:40 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Mar 17, 2023, 4:38 PM EDT - 2 years ago

Connect Biopharma stock up more than 40% after trial data

Mar 17, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Mar 6, 2023, 8:15 AM EST - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 6, 2023, 8:30 AM EST - 2 years ago

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Dec 30, 2022, 7:30 AM EST - 2 years ago

Connect Biopharma Provides Business and Clinical Development Program Update

Dec 19, 2022, 8:00 AM EST - 2 years ago

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Oct 27, 2022, 4:05 PM EDT - 2 years ago

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

Oct 4, 2022, 8:56 AM EDT - 2 years ago

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Oct 4, 2022, 7:00 AM EDT - 2 years ago

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Oct 3, 2022, 4:10 PM EDT - 3 years ago

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Sep 26, 2022, 12:13 AM EDT - 3 years ago

Connect Biopharma Is A Sleeper Heading Into October Data Readout

Sep 13, 2022, 8:51 PM EDT - 3 years ago

Connect Biopharma Holdings Limited (CNTB) Q2 2022 Earnings Call Transcript

YasirTrades Jul. 5 at 3:26 AM

0 · Reply

Doozio Jul. 4 at 4:22 PM

$CNTB if Ksha is here da 🧠 must be near. 🐒🍌🧠⏰♾️

0 · Reply

RollingDollars Jul. 3 at 2:42 PM

$CNTB

0 · Reply

kshonstocks Jul. 3 at 2:32 PM

$CNTB on scans, has the higher highs

0 · Reply

mikeywo Jul. 3 at 2:28 PM

$CNTB is this being discovered ? Glad I got in at .61c

0 · Reply

Bcscoatings Jun. 24 at 3:44 PM

$PSTV shorts got what they wanted now time for us to get what we want!! Time to go!! About to break that 100 million in volume !!! $CNTB $IGC

0 · Reply

mikeywo Jun. 24 at 3:33 PM

$CNTB what happened Barry ? You let the momentum up to 1.12$ go to waste.

0 · Reply

Bcscoatings Jun. 20 at 3:56 PM

$PCSA volume insane and still picking up. Reminds me $HCTI it went from .007-.04 huge volume 2 days in a row!!!! Bout to hit big here gain too!! $CNTB $CHSN $ELTP

0 · Reply

TheWings977 Jun. 17 at 9:58 PM

$CNTB back to $1. What’s the minimum to stay listed?

0 · Reply

RollingDollars Jun. 17 at 1:59 PM

$CNTB

0 · Reply

PenkeTrading Jun. 17 at 8:17 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Connect Biopharma Holdings Ltd. Is that bullish or bearish? $CNTB #RsiOverbought #NASDAQ

1 · Reply

Thestocktraderhubzee Jun. 16 at 11:05 AM

WATCHLIST JUN 16 2025. $AIOT Powerfleet Expands Deployment Of Advanced AI Video Safety Solution With EverDriven Technologies $LLY Eli Lilly Announces That The Highest Approved Doses Of Zepbound (Tirzepatide)—12.5 mg And 15 mg—Will Soon Be Available In Single-dose Vials For $499 Per Month Through LillyDirect's Self Pay Pharmacy Solutions And The Zepbound Self Pay Journey Program $LIQT Ascendiant Capital Maintains Buy on LiqTech International, Raises Price Target to $3.6 $CNTB Connect Biopharma Presents Clinical Data Supporting Rademikibart, Anti-Interleukin-4-Receptor Alpha Antibody At EAACI 2025 Annual Congress $TTE TotalEnergies Partners With Petronas In Multiple Blocks Offshore Malaysia And One Block Offshore Indonesia

0 · Reply

RunnerSignals Jun. 13 at 8:31 PM

Big Movers Making Noise! $TORO $SSL $CNTB $ELVN $SEDG Eyes on Monday's action! https://stocksrunner.com/news/2025-06-13-top-stock-market-movers-surge-on-big-news

0 · Reply

mikeywo Jun. 13 at 7:02 PM

$CNTB come on Barry 1$ is in sight.

0 · Reply

RollingDollars Jun. 13 at 6:31 PM

$CNTB

0 · Reply

QuiverQuant Jun. 13 at 2:56 PM

Connect Biopharma Reports Positive Clinical Results for Rademikibart in Eosinophilic-Driven Type 2 Asthma Patients Read more on $CNTB: https://www.quiverquant.com/news/Connect+Biopharma+Reports+Positive+Clinical+Results+for+Rademikibart+in+Eosinophilic-Driven+Type+2+Asthma+Patients

0 · Reply

RollingDollars Jun. 13 at 2:08 PM

$CNTB

0 · Reply

JarvisFlow Jun. 12 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Connect Biopharma Hldgs ( $CNTB ), setting the rating to Buy with a target price of 7.

0 · Reply

DonCorleone77 Jun. 10 at 8:39 PM

$CNTB Connect Biopharma files $300M mixed securities shelf

0 · Reply

DARKP00L Jun. 3 at 1:09 PM

$CNTB 09:06 on Jun. 03 2025 Connect Biopharma Announces Reduction in Annualized Exacerbations With Rademikibart in Eosinophilic Driven, Type 2 Asthma Oral Presentations And Improvement In Lung Function with Rademikibart In Eosinophilic Driven, Type 2 Asthma In Two Oral Presentations At European Academy Of Allergy And Clinical Immunology 2025 Annual Congress #tradeideas

1 · Reply

RollingDollars Jun. 2 at 10:26 AM

$CNTB

0 · Reply

Billianas May. 20 at 8:14 PM

$CNTB expecting it to break 1$ at anytime, then run to 2$+ and stabilize in this range, before a major run early 2026, 6$ can be possible here

0 · Reply

Market Cap	64.97M
Revenue (ttm)	26.03M
Net Income (ttm)	-15.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60.05%
Debt to Equity Ratio	0.00

Volume	82,500
Avg Vol	84,274
Day's Range	N/A - N/A
Shares Out	55.56M
Stochastic %K	79%
Beta	-0.20
Analysts	Strong Sell
Price Target	$6.50